Solid Biosciences Inc.
HealthcareNASDAQ:SLDB · NASDAQ Global Select
-$0.08 today
Vol 1.55M · Avg 1.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-96.8%
avg -44.5%
ROIC
-89.1%
avg -67.9%
ROA
-75.0%
avg -55.9%
Analysis
ROA is currently the strongest return metric at -75.0% versus its period average of -55.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexander G. Cumbo | President, Chief Executive Officer & Director | $1.11M | — | 55 | $235,405.00 | 0.30% |
David Tyronne Howton Jr. | Chief Operating Officer & Secretary | $791,718.00 | — | 54 | $105,077.00 | 0.13% |
Gabriel Brooks | Chief Medical Officer | $772,732.00 | — | 49 | $89,466.00 | 0.11% |
Kevin Tan | Chief Financial Officer & Treasurer | $607,181.00 | — | 48 | $99,422.00 | 0.13% |
Ian F. Smith | Executive Chair | $75,000.00 | — | 60 | $77,500.00 | 0.10% |
Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director | $40,000.00 | — | 52 | $77,500.00 | 0.10% |
Shuli Kulak | Head of Corporate Strategy & Business Development | — | — | — | — | — |
Annie Ganot | Co-Founder & Vice President of Patient Advocacy | — | — | — | $77,500.00 | 0.10% |
Nicole Anderson | Senior Director of Investor Relations & Corporate Communications | — | — | — | — | — |
Paul Herzich | Chief Technology Officer | — | — | 48 | $72,638.00 | 0.09% |
Jessie Hanrahan | Chief Regulatory & Preclinical Operations Officer | — | — | 50 | $74,318.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$2.68M
Net Sentiment
$2.68M
Net selling
Most Active
Ganot Ilan
5 transactions
1–10 of 29
Analysis
Insiders reported 0 buys worth $0.00 and 29 sells worth $2.68M over the last 12 months. That adds up to net selling of $2.68M. Ganot Ilan was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Who manages SLDB?
Solid Biosciences Inc. (SLDB) lists 11 active executives. The top listed executive is Shuli Kulak, Head of Corporate Strategy & Business Development.
Are SLDB insiders buying or selling?
Recent insider activity shows net buying of $47.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.